Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

Seeking Alpha | Sep 28, 2026 2:43 PM EDT